Mast Therapeutics Inc (NYSEMKT:MSTX), a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure, today reported financial results for the …
Healthcare analysts weigh in today on biotech companies Synergy Pharmaceuticals Inc (NASDAQ:SGYP) and Mast Therapeutics Inc (NYSEMKT:MSTX). The analysts positively viewed SGYP’s Plecanatide NDA submission, …
Following J.P.
In a research report issued Friday, Canaccord analyst John Newman reiterated a Buy rating on shares of Mast Therapeutics Inc (NYSEMKT:MSTX), with a $3.00 …
Analysts are weighing in on the clinical biopharmaceutical company Mast Therapeutics Inc (NYSEMKT:MSTX) and development stage company TG Therapeutics Inc (NASDAQ:TGTX), with positive ratings and views. …
In a research report published Thursday, Roth Capital analyst Michael Higgins reiterated a Buy rating on shares of Mast Therapeutics Inc (NYSEMKT:MSTX) with …
Canaccord’s healthcare analyst John Newman weighed in today with a few insights on Mast Therapeutics Inc (NYSEMKT:MSTX), after the company hosted an Analyst Day to highlight …
Mast Therapeutics Inc (NYSEMKT:MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle …
